Sastasundar Ventures Limited has informed the Exchange about Transcript
HEALTHX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sastasundar Ventures held an earnings call to discuss Q4 FY25 results, focusing on its post-Flipkart Health transition to an independent healthcare platform. The company's B2B business RetailerShakti nearly doubled revenue to around INR 941 crore in FY25 (from INR 489 crore in FY24), while the new B2C SastaSundar app generated INR 144 crore in its first full year. The company reported negative EBITDA for FY25 due to the B2C reset and largely unchanged fixed costs. Management outlined plans to invest about INR 50 crore in the B2C platform in FY26, guided for 100% B2C revenue growth this year, and targeted blended EBITDA margins of 4-5% by FY30 (7% for SastaSundar, 4% for RetailerShakti). Liquid assets stood at INR 656 crore, and management said no capital raise is planned for the next 2-3 years.
Short-term: Negative EBITDA persists as the company invests in rebuilding its B2C business after losing the Flipkart partnership. Medium-to-long term: Clear growth path with strong B2B momentum and a defined margin roadmap, but execution risk is high and management itself urged investors to think in 5-year terms, suggesting the stock may remain volatile around quarterly results.